Home

Senti Biosciences, Inc. - Common Stock (SNTI)

4.3300
-0.1300 (-2.91%)

Senti Biosciences, Inc. is a biotechnology company focused on developing innovative cell and gene therapies using its proprietary platform to enhance the therapeutic potential of engineered cells

The company utilizes advanced synthetic biology techniques to create intelligent and programmable therapies designed to target specific diseases with greater precision. By harnessing the power of genetic engineering, Senti aims to address unmet medical needs, particularly in the areas of cancer and other serious conditions, ultimately improving patient outcomes through its cutting-edge research and development initiatives.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close4.460
Open4.464
Bid4.060
Ask4.330
Day's Range4.295 - 4.487
52 Week Range1.520 - 16.94
Volume24,072
Market Cap11.92M
PE Ratio (TTM)-0.4774
EPS (TTM)-9.1
Dividend & YieldN/A (N/A)
1 Month Average Volume65,639

News & Press Releases

How Is The Market Feeling About Senti Biosciences?benzinga.com
Via Benzinga · January 1, 2025
AT&T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · December 4, 2024
US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&P Hits 54th All-Time High This Year: Analyst Sees 'Further Upside' Of Around 10% In 2025 From Current Levelsbenzinga.com
U.S. stock futures were in negative territory during Tuesday’s premarket hours as the dollar slipped to 106.3 level.
Via Benzinga · December 3, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 2, 2024
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimatesbenzinga.com
Via Benzinga · December 2, 2024
SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024investorplace.com
Senti Biosciences just reported results for the second quarter of 2024.
Via InvestorPlace · August 13, 2024
SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024investorplace.com
Senti Biosciences just reported results for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
Why Is Senti Biosciences Stock Surging Over 400% On Monday?benzinga.com
Senti Biosciences shares surge as SENTI-202 trial shows promise in AML patients; company secures $37.6M in private equity funding.
Via Benzinga · December 2, 2024
Nasdaq Gains Over 100 Points; Li Auto Delivers 48,740 Vehicles In Novemberbenzinga.com
Via Benzinga · December 2, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · September 25, 2024
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024
By Senti Biosciences, Inc. · Via GlobeNewswire · July 16, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 4, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesdayinvestorplace.com
Pre-market stock movers are worth diving into this morning as we break down all of the biggest news moving shares on Tuesday!
Via InvestorPlace · July 2, 2024
Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices.
Via MarketBeat · July 2, 2024
Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?benzinga.com
Senti Biosciences shares are trading higher by 102.6% during Monday's session. The company was awarded $8 million from the California Institute for Regenerative Medicines.
Via Benzinga · July 1, 2024
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia
By Senti Biosciences, Inc. · Via GlobeNewswire · July 1, 2024
Why Is Beyond Air (XAIR) Stock Down 22% Today?investorplace.com
Beyond Air stock is down on Tuesday as investors in XAIR react to the company mixed earnings report for the first quarter of the year.
Via InvestorPlace · June 25, 2024
Why Is Faraday Future (FFIE) Stock Down 27% Today?investorplace.com
Faraday Future stock is down on Tuesday after the troubled EV company announced plans for a reverse split of FFIE shares.
Via InvestorPlace · June 25, 2024
Why Is Senti Biosciences (SNTI) Stock Up 32% Today?investorplace.com
Senti Biosciences stock is up on Tuesday with heavy pre-market trading of SNTI shares despite a lack of news from the company.
Via InvestorPlace · June 25, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesdayinvestorplace.com
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!
Via InvestorPlace · June 25, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · June 7, 2024
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy –
By Senti Biosciences, Inc. · Via GlobeNewswire · May 13, 2024
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 –
By Senti Biosciences, Inc. · Via GlobeNewswire · May 9, 2024
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML –
By Senti Biosciences, Inc. · Via GlobeNewswire · April 30, 2024
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023investorplace.com
SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 21, 2024